In a follow-up Phase I/II study of R/R CD30+ lymphomas, treatment with AFM13 in combination with pre-complexed cord blood (cb)-derived allogeneic NK cells that were IL-12/IL-15/IL-18-preactivated and subsequently ex-vivo expanded resulted in an ORR of 94% and CRR of 71% for those treated at the recommended Phase II dose (R2PD) (n = 36); however, the vast majority of patients had classical Hodgkin lymphoma (cHL) rather than PTCL [59]. The gene discussed is TNFRSF8; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.